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Introduction {#sec001}
============

Cutaneous leishmaniasis (CL) is a zoonotic, vector-borne parasitic disease that affects 0.7--1 million mostly young patients every year \[[@pntd.0008050.ref001], [@pntd.0008050.ref002]\]. Despite the high incidence rate and vast geographic expansion, spreading throughout the Mediterranean, South American and Middle Eastern countries \[[@pntd.0008050.ref001], [@pntd.0008050.ref002]\], CL remains a neglected tropical disease with few effective intervention strategies \[[@pntd.0008050.ref003]\]. Clinically, CL usually presents as small papules at the site of infection that may progress to form nodules and then open sores with raised borders and central ulcers that can be covered with scales or crust. The lesions are usually painless but can be painful, particularly if superinfected with bacteria. While most lesions heal within 18 months, they can result in disfiguring scars that lead to life-long social stigma and economic loss \[[@pntd.0008050.ref003]--[@pntd.0008050.ref005]\]. Depending on the parasite strain and the immune response it elicits, CL can also take the form of diffuse cutaneous leishmaniasis, disseminated cutaneous leishmaniasis, Leishmania recidivans, or adopt the mutilating mucocutaneous form, which is harder to control \[[@pntd.0008050.ref001]--[@pntd.0008050.ref003]\].

Current treatment options for leishmaniasis include pentavalent antimonials (Sb^V^: sodium stibogluconate or meglumine antimoniate), amphotericin, miltefosine, and pentamidine. However, due to availability, cost, and relative safety and efficacy, Sb^V^ developed in the 1930's, remains the primary drug employed against CL \[[@pntd.0008050.ref003], [@pntd.0008050.ref006]\]. In several studies, treatment with Sb^V^ accelerated healing of CL lesions when used at 10--30 mg/kg/day IV or IM for 20--30 days, but the success rate ranges between 25 and 90% depending on the population and the strain of *Leishmania*, and even at the higher doses there are relapses \[[@pntd.0008050.ref003], [@pntd.0008050.ref007]\]. Importantly, this prolonged high-dose treatment regimen is associated with severe adverse effects including cardiotoxicity (prolonged QTc interval, premature beats, tachycardia, fibrillation), pancreatitis, liver and kidney toxicities, malaise, myalgia, and anorexia \[[@pntd.0008050.ref008], [@pntd.0008050.ref009]\]. Lastly, there are growing reports in India, Iran, and Peru of emerging resistance to antimonials in the field \[[@pntd.0008050.ref010]--[@pntd.0008050.ref014]\]. Several studies have explored reducing the dose or shortening the course of antimonial treatment to improve compliance and reduce toxicities with limited success \[[@pntd.0008050.ref015], [@pntd.0008050.ref016]\].

It is well established that the clinical outcome in CL is determined by the type of parasite and the immune response of the host \[[@pntd.0008050.ref017], [@pntd.0008050.ref018]\]. In subjects who produce antibodies to the parasite but do not mount adequate cellular immune responses, CL can evolve into a disseminated form of the disease with multiple large lesions \[[@pntd.0008050.ref003]\]. Conversely, in patients that mount strong Th1 responses CL can present with an aggressive form called mucosal leishmaniasis \[[@pntd.0008050.ref018]\]. Thus, interventions to modulate the immune response to the parasite and improve the disease outcome must negotiate a fine balance in which cellular responses are enhanced without leading to excessive inflammation or excessive cytolytic responses \[[@pntd.0008050.ref003], [@pntd.0008050.ref018]\]. To date, most immunomodulatory treatments have centered around topical applications of innate immune response modifiers, such as imiquimod (TLR7/8 agonist) or GM-CSF to aide lesion healing, albeit with mixed results \[[@pntd.0008050.ref019]--[@pntd.0008050.ref022]\]. However, studies that combined heat-killed *Leishmania* promastigotes and bacille Calmette-Guérin (BCG) with low dose antimonials for patients with CL or PKDL suggested that the addition of immune modulators could achieve comparable efficacy to full dose antimonials with fewer adverse effects \[[@pntd.0008050.ref023], [@pntd.0008050.ref024]\]. Lastly, there are some studies suggesting that imiquimod induces the activation of dendritic cells and the production of type I interferons, improving the efficacy of Glucantime therapy in *L*. *major* patients, although topical imiquimod can induce psoriatic-like lesions \[[@pntd.0008050.ref019], [@pntd.0008050.ref025]\]. Together these studies suggest that the addition of an immune response modulator may allow for shorter treatment courses, reducing toxicities and lowering the risk of the development of resistance; however, a safe and effective regimen has yet to be identified \[[@pntd.0008050.ref023]\].

Rhesus macaques are a useful model for testing therapies for CL as intradermal challenges with metacyclic promastigotes induce the formation of a lesion that recapitulates the evolution of the lesions in patients. In this model, 3--4 week regimens of antimonials at 20mg/kg/d reduce the severity of the CL lesions, but courses with reduced or abbreviated therapies show minimal or transient therapeutic effect \[[@pntd.0008050.ref026]\]. We have previously shown that treatment with type D CpG ODN improves the outcome of *L*. *amazonensis* or *L*. *major* infections in macaques. Administration of type D CpG ODN 3 days before or up to 15 days post-infection can reduce the lesion severity regardless of route (ID, IM or SC) suggesting that the product induces a systemic immunomodulatory effect \[[@pntd.0008050.ref027]--[@pntd.0008050.ref029]\]. Importantly, even with the reduction in lesion size and accelerated healing, the animals developed long-lasting protective memory responses to the parasite \[[@pntd.0008050.ref029]\]. Lastly, the improved response was evident even in macaques with simian AIDS, an important concern given the overlap in endemic areas \[[@pntd.0008050.ref030]\].

Type D CpG ODNs are short synthetic oligonucleotide sequences that have a single PuPyCpGPuPy motif surrounded by self-complementary bases \[[@pntd.0008050.ref031]\]. They selectively stimulate TLR9-bearing human and non-human primate plasmacytoid DC (pDC) to secrete IFNα \[[@pntd.0008050.ref032]\], which in turn leads monocytes to mature into functionally active DC \[[@pntd.0008050.ref033]\], and NK cells to secrete IFNγ \[[@pntd.0008050.ref031]\]. Of note, D type ODNs have a 3′ end poly(G) motif, that can self-associate via Hoogsteen base-pairing to form parallel quadruplex structures called G-tetrads. The formation of multimers may contribute to the ODN's localization to early endosomes where it signals through TLR-9, however the formation of tetrads poses formidable challenges for the synthesis, purification, and characterization of CpG ODN type D and hinders its clinical development. Further, previous studies showed that different TLR ligands can synergize to augment their immunomodulatory effects even when present at very low levels \[[@pntd.0008050.ref034], [@pntd.0008050.ref035]\], and it was therefore possible that impurities in the research-grade D35 preparation used in previous studies could have contributed to its immunomodulatory and clinical effect. In these studies, we assess whether D35, manufactured under ultrapure conditions and formulated to avoid the formation of aggregates, induces an immunomodulatory effect that can be used to improve the response to a suboptimal regimen of Sb^V^. We demonstrate that administration of a single dose of highly purified D35 (1 mg/kg SC) in macaques challenged with *L*. *major*, prior to a short, low-dose antimonial (Sb^V^) regimen, reduced lesion size, and lowered time to re-epithelization compared to untreated or Sb^V^ only treated animals. Importantly, macaques receiving repeated and escalating doses of D35, that were over 10-fold higher than the effective dose, showed no toxicities. Together these results suggest that administration of D35 can safely enhance the efficacy of a therapeutic regimen with lower exposure to Sb^V^.

Materials and methods {#sec002}
=====================

Oligonucleotides {#sec003}
----------------

Gene Design, Inc (Japan) was contracted to synthesis a batch of ultrapure D35 (GGtgcat[cg]{.ul}atgcaggggGG, phosphorothioate bases in uppercase and phosphodiester bases in lowercase). D35 was supplied formulated with 5% maltose. Purity of D35 lots was checked by HPLC and PAGE gel, and endotoxin levels were found to be \< 0.5 EU/mg by Endosafe PTS (Charles River).

Mononuclear cell isolation and stimulation {#sec004}
------------------------------------------

Buffy coats from healthy human blood donors were obtained from the National Institutes of Health Department of Transfusion Medicine. Mononuclear cells were isolated by density gradient centrifugation of PBMCs over Ficoll-Hypaque as described \[[@pntd.0008050.ref036]\]. Cells were washed three times and cultured in RPMI 1640 supplemented with 10% heat-inactivated FCS, 1.5 mM l-glutamine, and 100 U/ml penicillin/streptomycin. In a 24 well multiplate, 5 × 10^6^ cells/well were cultured in the presence of 1 μM ODN D35. Where indicated, Sb^V^ (Pentostam-Sodium Stibogluconate, CDC) was added at the same time as D35. RNA was collected after 24 h of stimulation while supernatants were collected after 72 h and stored at -20°C until further analysis.

CAL-1 cell culture and stimulation {#sec005}
----------------------------------

CAL‐1 cells, a pDC cell line \[[@pntd.0008050.ref037]\], were provided by Dr. T. Maeda (Department of Island Medicine, Nagasaki University, Japan). Cells were cultured in RPMI supplement with 10% FBS, 1.5 mM l-glutamine, 100 U/ml penicillin/streptomycin, 1mM Na Pyruvate, 10 mM Hepes, and non-essential amino acids (ThermoFisher Scientific). Cells were supplemented with fresh media every 2--3 days and the concentration was kept between 0.3--1.5 x 10^6^ cells/ml. Cells were stimulated in a 48 well multiplate (ThermoFisher Scientific) at the final concentration of 1.6 x 10^6^ cells/ml. Cells were stimulated for 18 hours with D35. This time point was found to be optimal for assessing gene induction due to D35 stimulation. Media was removed, and RNA was isolated from the cells.

Nucleic acid analysis {#sec006}
---------------------

RNA was isolated from cells by the addition of Trizol (ThermoFisher Scientific, Fremont, CA) following the manufacturer's recommendations. Following RNA isolation, cDNA was synthesized using 1000 ng total RNA and MultiScribe reverse transcriptase (ThermoFisher Scientific). Gene expression was measured using standard qPCR, low density taqman array (human immunology panel) or by NanoString (NanoString, Seattle, WA). Gene expression in qPCR experiments were quantified using the ddCT method, and in NHP studies each animal's prestudy measurements were used as the reference. Gene expression by NanoString was determined using the nSolver v3.0 software and the advanced analysis module v1.1.5.

Cytokine quantification {#sec007}
-----------------------

Cytokine levels were analyzed by cytometric bead array. For human samples IFNα, IFNγ, CXCL10, and IL6 were measured (ThermoFisher Scientific). For macaque samples, IFNγ, IL8, IL10, IL15, and IL17 were measured using a custom kit from Millipore Sigma (Burlington, MA). The manufacturer's recommended protocol was followed, and plates were read on Luminex 200 system (MilliporeSigma).

Primate use, ethics statement {#sec008}
-----------------------------

These studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and using protocols 2016--17 and 2017--62 approved by the Food and Drug's Animal Care and Use Committee (ACUC) and conducted in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care's (AAALAC) guidelines. The animals were housed in approved facilities and monitored daily by veterinarians and facility personnel. The macaques were kept in double housing (paired), fed a complete diet that included fresh fruits and vegetables. The cages were arranged in large rooms to allow the monkeys visual, olfactory and auditory interactions with each other. Food and water were available ad libitum and vitamins were provided. The animals were also provided with environmental enrichment, such as toys designed especially for monkeys, to promote psychological well-being. All inoculations, measurements and biopsies were performed under anesthesia using Ketaject; 5--7 mg/kg of body weight (Phoenix Pharmaceuticals), anesthesia was reversed with atipamezole hydrochloride (Antisedan, 100 μg/kg of body weight; Zoetis Services).

D35 dose escalation study {#sec009}
-------------------------

Two male and two female cynomolgus macaques (*Macaca fascicularis*, 6-11yrs old; weights 4.3 kg to 12 kg), were housed at the National Institutes of Health Animal Center. Macaques were anesthetized with ketamine prior to all procedures (Ketaject; 5--7 mg/kg of body weight; Phoenix Pharmaceuticals), following the procedure the anesthetic was reversed with atipamezole hydrochloride (Antisedan, 100 μg/kg of body weight; Zoetis Services). Blood was collected via femoral vein and following blood collection animals were injected with D35 in the chest (SC). Twenty-four hours after D35 administration, animals were anesthetized again and 5 mm skin biopsies (Miltex, Inc) were taken at the site of D35 administration or on the contralateral side of the chest. D35 injections were performed on alternating sides of the thorax and at least 2 inches away from a previous biopsy site to minimize the confounding effect of any residual inflammation due to a previous injection or biopsy. For a visual representation see [S1 Fig](#pntd.0008050.s002){ref-type="supplementary-material"}. Skin biopsies were placed immediately into Trizol and kept on ice until samples could be processed. A rectal temperature was taken before D35 administration and 24 h after D35 administration when the animals were anesthetized. One week after D35 administration macaques were again anesthetized and blood was collected via the femoral vein. Animals were allowed to recover for an additional 14 days before the next dose of D35 was administered.

*In vivo* interaction between D35 and Sb^V^ {#sec010}
-------------------------------------------

Male rhesus macaques (*Macaca mulatta*) were obtained from the National Institutes of Health (NIH) colony in South Carolina \[[@pntd.0008050.ref038]\], housed in approved facilities, and monitored daily by veterinarians and facility personnel. Animals were 2 years of age, and their average weight was 3.4 kg (range 2.6-4kg). Treatment groups were balanced for weight prior to starting the study. Animals were grouped into five groups based on the following treatments, Saline, Sb^V^ 20 mg/ml, Sb^V^ 5 mg/ml, Sb^V^ 2.5 mg/kg, Sb^V^ 0 mg/ml. Following 3 doses of Sb^V^ given every other day IM, the animals in groups Sb^V^ 20, 5, 2.5, 0 mg/kg were given a single dose of D35 1 mg/kg SC at a distant site. Blood and 4 mm skin biopsies (Miltex, Inc) were taken distant from the sites were drugs were previously administered. Skin biopsies were placed immediately into Trizol and kept on ice until samples could be processed. Macaques were anesthetized with ketamine for all procedures (Ketaject; 5--10 mg/kg of body weight; Phoenix Pharmaceuticals), following the procedure the anesthetic was reversed with atipamezole hydrochloride (Antisedan, 100 μg/kg of body weight; Zoetis Services). The animals showed no sign of itching or pain related to the lesions or the biopsies and efforts were made to minimize their suffering.

The impact of D35 on *L*. *major* infection {#sec011}
-------------------------------------------

Male and female rhesus macaques (*M*. *mulatta*) were obtained from the NIH colony in South Carolina \[[@pntd.0008050.ref038]\] and housed in FDA AAALAC accredited facilities. Animals ranged in age from 2 to 6 years, and the average weight was 4.2 kg (range 2.6--9.62 kg). Treatment groups were balanced for age and gender and assigned prior to starting the study. Macaques (n = 3-4/group) were challenged intra-dermally (ID) with 3 x10^6^ metacyclic promastigotes on the forehead at three separate sites (1 on the right and 2 on the left). The inoculation on the right remained untouched until the resolution of the lesions and used for lesion measurements, while the two on the left were used for biopsies at 11- and 22- days post infection (DPI). Lesion size was monitored by a blinded researcher measuring an untouched lesion (in mm) and by digital photography every 2--3 days for the first 4 weeks, followed by weekly measurement from then on. When 70% of lesions measured greater than 3 x 3mm, half the macaques were treated with D35 (1 mg/kg SC) or saline, in the hind quarters. Three days following D35 administration, the course of daily administration of Sb^V^ (5 mg/kg/d for 10 days, IM in the thigh) was initiated. This resulted in four treatment groups for the animals defined as group 1-Saline, group 2-Sb^V^, group 3-D35, and group 4-D35 + Sb^V^. Graphical representation of study layout can be found in [S2 Fig](#pntd.0008050.s003){ref-type="supplementary-material"}. Blood, serum samples and 4 mm diameter punch biopsies (Miltex, Inc) of the forehead skin were obtained at 11- and 22 DPI. Skin biopsies were divided into three pieces; two were immediately frozen in liquid nitrogen while the third was submerged in TRIzol and stored at -80°C until processing. Macaques were anesthetized with ketamine for all procedures (Ketaject; 5--10 mg/kg of body weight; Phoenix Pharmaceuticals), following the procedure the anesthetic was reversed with atipamezole hydrochloride (Antisedan, 100 μg/kg of body weight; Zoetis Services). All experiments were approved by the Animal Care and Use Committee (ACUC), conducted in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care's (AAALAC) guidelines, the animals were housed in approved facilities and monitored daily by veterinarians and facility personnel.

*L*. *major* clone VI promastigotes (MHOM/IL/80/Friedlin provided and prepared by Dr David Sacks, NIH) were maintained as follows: promastigotes were grown at 26°C in medium 199 (M199) supplemented with 20% heat-inactivated FCS (Gemini Bio-Products), 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM l-glutamine, 40 mM Hepes, 0.1 mM adenine (in 50 mM Hepes), 5 mg/ml hemin (in 50% triethanolamine), and 1 mg/ml 6-biotin (M199/S). Infective-stage metacyclic promastigotes were isolated from stationary cultures (5--6 d) by density gradient centrifugation and were grown and isolated as described previously \[[@pntd.0008050.ref039]\].

Tissue homogenization {#sec012}
---------------------

Samples for RNA extraction were thawed and mixed with 0.5 cm^3^ of 2.0 mm Zirconia Beads (Biospec). Tissue was homogenized using the Precellys 24, Cryolys system (Bertin Technologies) with the following settings: 3 cycles at 6800rpm, with 30s of alternate run and pause time, program was carried out twice. Homogenate was transferred to a clean 2 mL Eppendorf tube and total RNA was isolated as described above.

NanoString mRNA profiling {#sec013}
-------------------------

The NanoString nCounter NHP Immunology Panel (NanoString Technologies, Seattle, WA) was used for skin samples, and PBMC expression was analyzed with a custom panel of 85 genes ([S1 Table](#pntd.0008050.s010){ref-type="supplementary-material"}) per manufacturer's instructions. Briefly, probes were hybridized to 100 ng of total RNA for 19 h at 65°C, after which, excess capture and reporter probes were removed, and transcript-specific ternary complexes were immobilized on a streptavidin-coated cartridge. The code set contains a 3′ biotinylated capture probe and a 5′ reporter probe tagged with a fluorescent barcode, two sequence-specific probes for each of 770 transcripts. All solution manipulations were carried out using the NanoString preparation station robotic fluids handling platform. Data collection was carried out with the nCounter Digital Analyzer to count individual fluorescent barcodes and quantify target RNA molecules present in each sample. Normalization was performed based on a standard curve constructed using the spike in exogenous control samples. Background hybridization signal was determined using the spike in negative controls provided. mRNAs with counts lower than the mean background +2 standard deviations were considered to be below the limit of detection. The nSolver (v.3.0) user interface (Nanostring) was used to operate the nCounter advanced analysis module, which employs the R statistical software. The advanced analysis module was used to identify the mRNA transcripts that were significantly elevated above each animal's pre-study levels (p\<0.05). The differences in expression level comparing saline and D35 treatment for individual genes were tested by one tailed t test with an alpha of 0.1 (Graph pad Prism 7.0). The raw datasets generated during the current study are available from the corresponding author upon reasonable request.

To better understand the differences in gene expression between treated and untreated macaques, we analyzed the genes that were significantly different between the two groups (1 tailed t test, alpha = 0.1) using Ingenuity Pathway Analysis. Pathways which were disease specific and not relevant to the current study where removed see [S2 Table](#pntd.0008050.s011){ref-type="supplementary-material"} for complete list of enriched pathways.

Statistics {#sec014}
----------

All statistics were carried out using Prism 7 (Graphpad Software, La Jolla, CA) apart from the NanoString analysis. For analysis of Nanostring data, nSolver^TM^ v3.0 was used. Briefly, gene expression was first normalized to positive and negative controls and then to the geometric mean of housekeeping genes (*ABCF1*, *HPRT1*, *POLR2A*, *SDHA*, *TBP*, *TUBB*). The changes in gene expression were assessed as counts of mRNA relative to each animal's baseline. Hierarchical clustering was carried out using Ward's minimum variance method in R. The determination of which genes were significantly increased over their paired pre-study state was analyzed using the advanced analysis module v1.1.5 of nSolver. T tests (α 0.1) were used to test differences in gene expression between saline and D35 samples. All analyses involving more than two groups were performed by ANOVA followed by Tukey's multiple comparisons test.

Results {#sec015}
=======

Characterization of ultrapure type D CpG ODN D35 {#sec016}
------------------------------------------------

Type D CpG ODN have been shown to act as innate immune modulators stimulating plasmacytoid dendritic cells to produce type I IFNs, IFN-inducible genes (ISG), and effectively reducing the severity of lesions in macaques infected with *L*. *major* \[[@pntd.0008050.ref040]--[@pntd.0008050.ref042]\]. Their activity has been linked to a single CpG motif encased in a self-complementary core sequence and a 3′ end poly(G) track that favors G-tetrad formation leading to multimerization. Although multimerization appears necessary for intracellular localization to early endosomes and signaling via Toll-like receptor 9 (TLR-9), it can result in product polymorphisms with an increased risk of uncontrolled aggregation and precipitation during manufacture, thereby hampering their clinical development \[[@pntd.0008050.ref031], [@pntd.0008050.ref043], [@pntd.0008050.ref044]\]. To examine whether biological activity would be reduced if the product's multimerization was controlled, a highly purified synthetic oligonucleotide was formulated in 5% maltose to produce an ultrapure lot of CpG ODN D35 (D35) with low levels of impurities and aggregates ([S2 Fig](#pntd.0008050.s003){ref-type="supplementary-material"}). To assess its biological activity, we compared the mRNA expression pattern for 90 immune-related genes in PBMCs stimulated with either research grade D35 or ultrapure D35 (1μM). As shown in [Fig 1A and 1B](#pntd.0008050.g001){ref-type="fig"}, despite reduced multimerization, both batches of D35 induced a similar gene expression profile in PBMC of healthy blood donors (r = 0.96; p\<0.001). However, closer examination of the levels of mRNA induced by each lot suggested that there were subtle differences in the magnitude of the response for some genes ([Fig 1B](#pntd.0008050.g001){ref-type="fig"}). This was confirmed when we assessed the levels of individual cytokines in supernatants at 72 h. While all lots of D35 induced similar levels of CXCL10, the ultrapure oligos induced significantly lower level of IFNα and IL6 as well as a trend towards lower levels of IFNγ that did not reach statistical significance but could be clinically relevant ([Fig 1C](#pntd.0008050.g001){ref-type="fig"}). As expected, the response in PBMC is quite variable from donor to donor, therefore we next established a cell line-based assay to reproducibly monitor the bioactivity of D35 using the pDC Cal-1 cells. As shown in [Fig 1E](#pntd.0008050.g001){ref-type="fig"}, research grade D35 and ultrapure D35 induced similar levels of MX-1 in these cells when used at 0.3--3 μM, however, at higher concentrations of D35 (\>6 μM), the induction of MX-1 was more modest for the formulated than the research grade D35. While the lower activity of D ODN that do not form aggregates is consistent with previous reports, these studies suggested that the ultrapure D35 conserves its immunomodulatory activity at concentrations previously shown to be immunostimulatory *in vitro* \[[@pntd.0008050.ref028], [@pntd.0008050.ref030], [@pntd.0008050.ref040]\]. Lastly, to establish that both ODN stimulated PBMC from primates, we stimulated human and rhesus macaque PBMC with 0.3 and 1 μM of D35 for 24 h. As shown in [Fig 1D](#pntd.0008050.g001){ref-type="fig"}, both preparations induced similar mRNA levels of MX-1, confirming that non-human primates are a good model to test the activity of these ODN *in vivo*. In summary, the *in vitro* data suggested that ultrapure D35 induced a similar response to research grade D35 despite the reduced formation of aggregates and reduced impurities, thus all ensuing studies were conducted using the ultrapure D35.

![D35 formulation reduces product aggregates.\
PBMCs from healthy donors (n = 3--5; 4 x 10^6^ cells/ml) were stimulated in triplicate in a 24 well plate with ultrapure or research grade D35 (1 μM). The induction of 88 immune related genes by ultrapure and research grade D35 after 24 h of stimulation is shown by scatter plot (A) and heatmap (B). Degree of correlation was calculated in Prizm 7 and gene clustering in the heatmap was calculated by Ward's minimum variance method in R. mRNA for *MX1* shows similar dose-dependent levels of mRNA expression by qPCR in response to *in vitro* stimulation. (C) Cytokine levels in supernatants of PBMCs stimulated for 72 h in the presence of 1 μM D35 (Mean ± SD of 3--5 donors). (D/E) PBMC (D) (4 x 10^6^/ml stimulated in a 24 well plate) or CAL-1(E), a human pDC cell line (3.33 x 10^6^/ml stimulated in a 48 well plate), were incubated with increasing concentrations of D35 as indicated, and expression of *MX1* mRNA, a type I IFN response gene, was used as a surrogate for IFN-α production after 24 h in culture. Data from PBMC were generated using PBMC from 3--5 healthy human donors and 8 adult macaques. CAL-1 experiments were performed at least 3 separate times in triplicate. \*\* indicates p\<0.01 and \*\*\* indicates p\<0.001. All statistics with human PBMCs were calculated using a paired analysis. CAL-1 data was analyzed by t-test.](pntd.0008050.g001){#pntd.0008050.g001}

To confirm the activity of the D35 *in vivo*, we next inoculated three cynomolgus macaques in the torso (SC) with increasing doses of D35 at three-week intervals ([S1 Fig](#pntd.0008050.s002){ref-type="supplementary-material"}). A fourth macaque was inoculated every 3 weeks with saline and served as an experimental control. Skin biopsies collected 24 hours post inoculation showed increased expression of interferon stimulated genes (ISGs), *MX1*, *OAS1*, *CXCL10*, and *IRF7*, starting at 1 mg/kg at the site of injection (ipsilateral, local response at the inoculation site) as well as the contralateral (systemic response) side of the torso ([Fig 2A--2D](#pntd.0008050.g002){ref-type="fig"}). This indicated that D35 modifies the cytokine milieu beyond the inoculation site. At the injection site, the ISG expression levels were higher but appeared to plateau for doses higher than 3 mg/kg. In contrast, the contralateral biopsy showed a dose-dependent increase in mRNA expression levels. The minimal changes in mRNA expression for *IL6* and *IL8* in skin suggest that the pro-inflammatory effect of D35 is mild ([Fig 2E & 2F](#pntd.0008050.g002){ref-type="fig"}). Of note, skin biopsies taken 3 weeks after the last inoculation with D35 showed that the mRNA levels had not returned to baseline for MX1, OAS1, and CXCL10, suggesting that the systemic immunomodulatory effect of D35 is modest but sustained *in vivo*. The immune activation induced by D35 was also evident in peripheral blood, as treated macaques showed increased mRNA levels for *MX1*, *OAS1*, and *IRF7* at all concentrations tested ([Fig 2G--2J](#pntd.0008050.g002){ref-type="fig"}). Unlike the skin biopsies, the levels of mRNA expression in PBMC returned to baseline 7 days post-treatment except for macaque C71, which showed relatively higher levels of *MX-1* and *IRF7* mRNA levels in peripheral blood 7 days after receiving the 6, 9, and 12 mg/kg doses. Three weeks after the last dose, the ISG mRNA levels in peripheral blood had returned to baseline. As observed in skin, D35 did not induce detectable increases in *IL6* or *IL8* in PBMC confirming the mild pro-inflammatory effect of D35 ([Fig 2K & 2L](#pntd.0008050.g002){ref-type="fig"}). Importantly, no fever, changes in CBC, chemistry panel, or weight were evident during the study ([S3 Table](#pntd.0008050.s012){ref-type="supplementary-material"}). Lastly, autopsies of the macaques did not show any pathologic changes. Together these data indicate that the ultrapure D35 has biological activity despite having reduced impurities. Given that D35 induces detectable local and systemic biological activity at 1 mg/kg, which is the dose previously used to treat CL in macaques, this dose was used to explore the use of D35 as an adjunct treatment to reduce the dose of Sb^V^.

![Local and systemic response to administration of increasing doses of D35 *in vivo*.\
Three monkeys received increasing doses of D35 and one received saline The monkeys were injected subcutaneously on alternating sides of the chest with 1, 3, 6, 9, and 12 mg/kg at 3- week intervals. Blood samples were collected prior to each SC D35 injection, as well as 1- and 7-days post-injection, after which the monkeys were rested for two weeks and then a new cycle started. A final sampling cycle was taken after the last inoculation to assess whether mRNA levels had reverted to baseline. Skin biopsies were collected from the site of injection (ipsilateral) and on the contralateral side of the chest 24 hours post-treatment to assess the local and systemic effect of the treatment on skin. mRNA expression levels were measured by qPCR. (A-F) shows the individual mRNA levels at ipsilateral and contralateral sites. (G-L) Shows gene expression from PBMCs.](pntd.0008050.g002){#pntd.0008050.g002}

In vitro interaction of Sb^V^ and D35 {#sec017}
-------------------------------------

Antimonials are the first line treatment for CL. Their mechanism of action is incompletely understood, but they are thought to act by priming the respiratory burst of phagocytes, increasing the sensitivity of cells to cytokines and interferons, and directly decreasing parasite DNA, RNA, protein synthesis \[[@pntd.0008050.ref045]--[@pntd.0008050.ref047]\]. While Sb^V^ and D35 have distinct mechanisms of action, it was unknown whether Sb^V^ would alter the immunomodulatory activity of D35 in CL. To explore whether the two treatments could be used in combination, we first determined whether Sb^V^ modifies the effect of D35 *in vitro*. PBMCs from healthy human blood donors were stimulated with 1μM D35 alone or in the presence of increasing concentrations of Sb^V^ (20, 100, 500 μg/ml). These doses correspond to the reported peak serum levels in NHP following administration of a 20mg/kg dose (20--40 μg/mL), and supramaximal concentrations of Sb^V^ (100 and 500 μg/mL) \[[@pntd.0008050.ref026], [@pntd.0008050.ref048]--[@pntd.0008050.ref050]\]. As expected, treatment with D35 induced the expression of IFNα, IFNγ, and CXCL-10 both at the mRNA (24h) and protein levels (72h) ([Fig 3](#pntd.0008050.g003){ref-type="fig"}). Treating the cells with 20 ng/ml Sb^V^ did not modify the cytokine levels in these cells ([Fig 3](#pntd.0008050.g003){ref-type="fig"}). In cells exposed to both, the presence of Sb^V^ in the culture did not significantly modify the mRNA response to D35 at concentrations consistent with Cmax for Sb^V^. At higher Sb^V^ concentrations, however the cells from some donors showed increased levels of mRNA for IFNα and IFNγ, as well as relatively increased levels of CXCL10 ([Fig 3A](#pntd.0008050.g003){ref-type="fig"}). Further, at 500 μg/ml of Sb^V^ there was a reduction in the levels of IFNα, CXCL10, and IFNγ induced by D35 in supernatants ([Fig 3B](#pntd.0008050.g003){ref-type="fig"}) suggesting that exposure to Sb^V^ could blunt the immune activation of D35, albeit at concentrations over 10-fold higher than expected in patients.

![Effect of Sb^V^ on D35-induced cytokine expression *in vitro*.\
Human PBMCs were treated with D35 (1μM) in the presence of increasing concentrations of Sb^V^ (0--500 μg/ml). A) Gene expression was analyzed after 24 h of stimulation by qPCR and expressed as fold change compared to each individual donor's unstimulated sample. B) Protein levels in 72 h supernatants were determined by Luminex. For gene expression n = 10, and for protein n = 6. Mean ± SD were calculated using Graphpad Prizm. \* indicated difference between untreated and D35 treatment, while \# indicates significant differences between baseline and Sb^V^ treated, where\* or \# for p \<0.05 and \*\* or \#\# for p\<0.01. Differences in gene expression were calculated using a paired analysis.](pntd.0008050.g003){#pntd.0008050.g003}

In vivo effects of Sb^V^ on D35 treatment {#sec018}
-----------------------------------------

As we had observed an effect of Sb^V^ on the response to D35 at high doses *in vitro*, we next examined whether Sb^V^ at clinically relevant doses could affect the *in vivo* response to D35. Rhesus macaques (n = 6/group) received three doses of Sb^V^ IM (0, 2.5, 5 or 20mg/kg) on 3 consecutive days followed by a single subcutaneous dose of D35 (1mg/kg SC). Saline treated animals were used as controls. The animals did not show any signs of Sb^V^ drug-related fever, loss of appetite, or muscle tenderness even at the highest dose regimen. As shown in [Fig 4A](#pntd.0008050.g004){ref-type="fig"}, treatment with D35 induced a detectable increase in mRNA for *MX1*, *CXCL10* and *IRF7* in PBMC (12.1, 5.7, and 2.7-fold respectively, relative to the baseline for each individual macaque). Treatment with Sb^V^ did not modify the induction of *MX1*, *CXCL10*, or *IRF7* regardless of dose.

![Sb^V^ effects on D35 signaling *in vivo*.\
Five groups of 5 rhesus macaques were treated with Sb^V^ at 0, 0, 2.5, 5, or 20 mg/kg/day IM for 3 days. On the 3rd day D35 (1 mg/kg SC) or saline were administered at a separate location. PBMCs and skin biopsies distant from site of drug administration were collected 24 h following the CpG ODN treatment. Cytokine mRNA levels were measured by qPCR. Individual animals represented by a unique symbol. n = 5, Geometric mean ± SD. \* \<0.05.](pntd.0008050.g004){#pntd.0008050.g004}

Since skin is the target organ for CL, we next determined whether D35 treatment induces a systemic change in gene expression in the skin. Full depth skin biopsies were obtained at a site distant from the administration site of either drug and tested for cytokine expression. As shown in [Fig 4B](#pntd.0008050.g004){ref-type="fig"}, following D35 administration the increase in mRNA levels for *MX1* (17.5 fold) and *CXCL10* (4.8 fold) in skin was quite variable between macaques, and we did not observe detectable changes in mRNA levels for *IRF7*. The D35-induced increase in mRNA expression was not modified by the Sb^V^ treatment ([Fig 4B](#pntd.0008050.g004){ref-type="fig"}). These data indicate that short-term systemic administration of clinically relevant doses of Sb^V^ does not impair the effect of D35 *in vivo*, despite the modulation of IFNα and IFNγ responses to CpG ODN observed *in vitro*. Additional studies will be needed to evaluate whether prolonged exposure in vivo could impair TLR9 responses.

Effect of Sb^V^ and D35 treatment on gene expression in macaques with cutaneous leishmaniasis {#sec019}
---------------------------------------------------------------------------------------------

Previous studies in macaques had established that challenges with *L*. *major* resulted in maculopapular lesions that heal within 10 weeks of challenge \[[@pntd.0008050.ref030]\]. Administration of a full course of Sb^V^ (20mg/kg for 20 days) in infected macaques, reduced the lesion severity and accelerated healing whereas, as previously reported, a suboptimal regimen of Sb^V^ (5 mg/kg for 10 days) did not \[[@pntd.0008050.ref026]\] ([S4 Fig](#pntd.0008050.s005){ref-type="supplementary-material"}). To determine whether the administration of D35 would improve the efficacy of a suboptimal regimen of Sb^V^, 15 rhesus macaques were assigned to 4 treatment groups: Group 1 Saline, Group 2 Sb^V^ 5 mg/kg (Sb^V^~lo~), Group 3 D35 1 mg/kg (D35)~,~ and Group 4 Sb^V^~lo~ plus D35. Macaques were challenged with 2 x 10^6^ *L*. *major* metacyclic promastigotes on 3 sites on the forehead (2 sites (for biopsies) on the left forehead and 1 on the right forehead (measurement of lesion development). Following the challenge with *L*. *major*, the macaques were evaluated each macaque every 2--3 days for the emergence of lesions ([S2](#pntd.0008050.s003){ref-type="supplementary-material"} and [S5](#pntd.0008050.s006){ref-type="supplementary-material"} Figs). Eight days post-infection (DPI) 14 of 15 macaques had developed at least 1 lesion larger than 3 mm in diameter so the treatment phase was initiated ([S5 Fig](#pntd.0008050.s006){ref-type="supplementary-material"}): Macaques in groups 3 and 4 were treated with a single dose of D35 SC in the hind quarters, while the macaques in groups 1 and 2 received saline (control) by the same route. At the time of D35 administration (8 DPI), there was no difference in the median lesion score between the macaques assigned to the saline or D35 groups (30±68.76 and 26.5±9.93, respectively) as measured on the right lesion site ([S5 Fig](#pntd.0008050.s006){ref-type="supplementary-material"}). Three days later (11 DPI), the lesion score had grown for most monkeys but was relatively smaller at 41±15.97 among D35-treated animals as compared to 135±79.01 in saline treated animals ([Fig 5A](#pntd.0008050.g005){ref-type="fig"}, p = 0.0215; [S5 Fig](#pntd.0008050.s006){ref-type="supplementary-material"}). To determine whether we could associate differences in clinical progression with changes in local or systemic mRNA levels for immune related genes, we collected peripheral blood and a skin biopsy of 1 lesion on the left side from all animals on day 11, prior to starting Sb^V^~lo~ treatment. The local (skin) and systemic (whole blood) mRNA levels were assessed by NanoString analysis (770 gene panel for skin and 70 gene panel for whole blood). The mRNA expression level for each animal was standardized to its own tissue-specific gene expression level at baseline.

![Effect of D35 on gene expression in blood following an in vivo infection with *L*. *major*.\
Fifteen rhesus macaques were challenged with 3 x10^6^ *L*. *major* parasites/challenge site (*L*. *major* metacyclic promastigotes, clone V1 promastigotes (MHOM/IL/80/Friedlin). After 8 days, 8 macaques were treated with D35 (1 mg/kg SC). mRNA expression in peripheral blood was assessed at day 11 and compared with baseline. (A) Lesion size at D11 post-infection. (B) The expression profile of 70 genes from an immune focused panel was measured by Nanostring and the number of genes that were significantly differentially regulated compared to pre-infected blood cells were determined. (C-Q) shows the expression of a subset of genes linked to type I IFN, T cell and NK cell activation (C-K). Each animal has been given a unique symbol. n = 6, geometric mean ± SD, \*p \< 0.05.](pntd.0008050.g005){#pntd.0008050.g005}

In whole blood, the individual differences in gene expression between treatment groups were more subtle, however, hierarchical clustering of gene expression identified a group of type I IFN-related genes in D35-treated macaques compared to infected controls ([Fig 5B](#pntd.0008050.g005){ref-type="fig"}). Eight of the nine classical type I IFN responsive genes in the array showed significant upregulation in D35 vs saline treated rhesus macaques' whole blood ([Fig 5C--5K](#pntd.0008050.g005){ref-type="fig"} and [S6A Fig](#pntd.0008050.s007){ref-type="supplementary-material"}) suggesting that D35 had induced a type I interferon response. These results were confirmed by qPCR for *MX1*, *OAS1*, and *CXCL10* ([S6B Fig](#pntd.0008050.s007){ref-type="supplementary-material"}). In addition, infected macaques treated with D35 tended to have lower levels of *IL23* and *IL17F* as well as relatively higher levels of TBET (*TBX21*), *CCL22*, granulysin, granzyme B, and perforin 1, suggesting increased levels of activated NK cells and a shift towards cytotoxic responses in peripheral blood ([Fig 5J and 5L--5Q](#pntd.0008050.g005){ref-type="fig"}).

In untreated macaques, skin biopsies of the lesion site 11 days post challenge show differential expression of 379 of 700 genes monitored (defined as \>2-fold expression change and p\<0.05 relative to each monkey's baseline) as compared to 404 among those treated with D35. Importantly, while the change in expression of most genes at the lesion site was driven by the parasite and similarly modified in both groups ([Fig 6A](#pntd.0008050.g006){ref-type="fig"}), the magnitude of the response for some genes varied by treatment ([S7 Fig](#pntd.0008050.s008){ref-type="supplementary-material"}; for a complete list of genes altered relative to background, see [S4 Table](#pntd.0008050.s013){ref-type="supplementary-material"} and [S5 Table](#pntd.0008050.s014){ref-type="supplementary-material"}). Pathway analysis indicated an enrichment of paths related to innate cell function and activation including DC maturation and increased TLR receptor signaling for animals treated with D35 relative to the ones that received saline ([Fig 6B](#pntd.0008050.g006){ref-type="fig"}). Indeed, the lesions in macaques treated with D35 had a trend towards increased levels of mRNA for chemokines that attract monocytes and neutrophils (*CCL2*, *CCL3*, *CCL5*) and adhesion molecules such as *SELE* and *SELL*, as well as a corresponding increase in genes related to APC maturation and antigen processing such as *CD80*, *CD86*, and MHC ([Fig 6C and 6D](#pntd.0008050.g006){ref-type="fig"}). Further, levels of mRNA for genes *IL1β*, *IL6*, *C3*, and *MMP9* were higher in lesions of D35 treated macaques indicating a proinflammatory environment. While no difference was observed in T cell associated markers *CD3*, *CD4* and *CD8*, markers for NK cells *SLAMF6* and *KLR1* were increased in D35 treated macaques along with increases in *IFN*γ, granzymes B and K, and *EOMES*, but not *IL10* and *IL4*, ([Fig 6E and 6F](#pntd.0008050.g006){ref-type="fig"} and [S4 Table](#pntd.0008050.s013){ref-type="supplementary-material"} and [S5 Table](#pntd.0008050.s014){ref-type="supplementary-material"}) suggesting the presence of activated NK and T cells. However, we did not observe a change in the expression of perforin or granulysin, which are also associated with the cytolytic function of NK cells and their ability to kill intracellular pathogens \[[@pntd.0008050.ref051]\]. Together these data indicate that systemic administration of D35 results in a reduction in the severity of *Leishmania* lesions that is associated with increased systemic type I IFN responses and possibly the activation of NK cells and macrophages.

![Effect of D35 on gene expression in skin following an in vivo infection with *L*. *major*.\
Fifteen rhesus macaques were challenged with 3 x 10^6^ *L*. *major* parasites/challenge site (*L*. *major* metacyclic promastigotes, clone V1 promastigotes (MHOM/IL/80/Friedlin). After 8 days, 8 macaques were treated with D35 (1 mg/kg SC). mRNA expression in biopsies of CL lesions was assessed at day 11 and compared with baseline. The expression profile of 770 genes from an immune focused panel were measured by Nanostring and the number of genes that were significantly differentially regulated compared to pre-infected skin was identified. A) Diagram showing the distribution of genes differentially regulated (\>2-fold change and p\<0.05) compared to pre-infected skin. B) Ingenuity pathway analysis of gene expression in D35-treated animals vs untreated controls. Mean expression of genes related to chemokines (C), antigen presentation (D), cytotoxic genes (E), and inflammation (F) are shown. Gene expression is expressed as fold change over pre-study baseline for each individual macaque. n = 6, mean ± SEM, \*p \< 0.05.](pntd.0008050.g006){#pntd.0008050.g006}

D35 treatment improves lesion progression {#sec020}
-----------------------------------------

Previous studies suggested that TLR agonists can improve the outcome in CL patients that receive standard of care treatment \[[@pntd.0008050.ref020]\]. To assess whether D35 could improve the response to an abbreviated, low-dose course of Sb^V^, 3 days after the administration of D35 or saline, 2 groups of macaques (saline- Sb^V^~lo~ or CpG ODN- Sb^V^~lo~) were started on a course of 5 mg/kg Sb^V^~lo~ (IM for 10 days). Similar low-dose antimonial courses were previously found not to be effective as single therapies in macaques challenged with *L*. *brazilensis* \[[@pntd.0008050.ref026]\] or *L*. *major* ([S4 Fig](#pntd.0008050.s005){ref-type="supplementary-material"}). As shown in [Fig 7](#pntd.0008050.g007){ref-type="fig"}, macaques that received Sb^V^~lo~ alone had lesions comparable in maximal size to untreated macaques. Further, 1 of the 3 macaques that received 5 mg/kg of Sb^V^ had a relapse with increased lesion severity immediately after the last dose of Sb^V^~lo~. In contrast, all the macaques that received a dose of D35 at 8 DPI developed milder lesions ([Fig 7A](#pntd.0008050.g007){ref-type="fig"}). In particular, the animals that received D35 followed by Sb^V^~lo~ developed smaller lesions and healed earlier ([Fig 7](#pntd.0008050.g007){ref-type="fig"}). The differences between groups were evident when comparing the maximum lesion score: 254.2±41.56 in Sb^V^~lo~ and 177.5±28.72 in saline-treated animals, as compared to 118.1±61.69 in D35 treated animals and 78.75±34.82 for those that received the combined treatment ([Fig 7C](#pntd.0008050.g007){ref-type="fig"}). Accordingly, re-epithelization of the ulcerated lesion took 17.5±4 days in animals treated with D35 and 14.25±7.4 days with Sb^V^~lo~+D35, as compared to 28.5±7.5 days for saline and 23.7±2.31 days for Sb^V^~lo~-treated animals ([Fig 7D](#pntd.0008050.g007){ref-type="fig"}). Parasite detection at the lesion site was performed using minicircle DNA qPCR at 11 or 22 DPI but failed to show significant differences in parasite loads in the lesions between groups ([S8 Fig](#pntd.0008050.s009){ref-type="supplementary-material"}), suggesting that the reduced lesion severity is linked to a reduced inflammatory response. Alternatively, because minicircle DNA is very stable, changes in live parasites was obscured. Overall, our results demonstrate that D35 improves the outcome in macaques that receive a low dose and shortened treatment course of Sb^V^~lo~ and identified no negative interaction between D35 and Sb^V^. This suggests that D35 could be used to improve the response to suboptimal regimens of Sb^V^ reducing the risk of SAE and potentially improving their efficacy.

![D35 reduces lesion size and improves healing in response to *L*. *major* infection.\
Fifteen rhesus macaques were challenged with 3 x 10^6^ *L*. *major* parasites/challenge site (*L*. *major* metacyclic promastigotes, clone V1 promastigotes (MHOM/IL/80/Friedlin). After 8 days, 8 macaques were treated with D35 (1 mg/kg SC). Macaques were then treated with Sb^V^ (5mg/kg/d IM from 11--20 DPI). Lesion size was measured over the course of the study. A) Evolution of lesion development for each animal is shown by treatment group. Lesion development over time was quantified as area under the curve (B), maximum lesion size (C), and days each monkey took to re-epithelize their ulcerated lesion (D). E) Numbers of L. major parasites were quantified by qPCR using minicircle DNA isolated from a portion of a skin biopsy. Absolute numbers of parasites were calculated using a standard curve generated from biopsy samples spiked with a known number of parasites. Parasites numbers were quantified at D11, D22 and D71 post infection. Stars (\*) indicate difference with saline-treated macaques. \# indicates difference with Sb^V^ treated macaques. n = 3-4/group, \*p \< 0.05, \*\* or \#\#p \< 0.01, \*\*\*p \< 0.001.](pntd.0008050.g007){#pntd.0008050.g007}

Discussion {#sec021}
==========

Pentavalent antimonials such as sodium stibogluconate and meglumine antimoniate are the most commonly used therapies for CL, but due to high cost, large dose, extended treatment regimes, and severe adverse events patient compliance is a major factor in disease treatment. the high dose and extended treatment regimens needed to control the parasites and cure the lesions can lead to severe adverse events and poor compliance. Further, their efficacy varies between 20 and 90%, depending on the geographic region and *Leishmania* strain and foci of resistance have been reported with increasing frequency \[[@pntd.0008050.ref014]\]. To improve the efficacy of antimonials, several studies have tested the use of immune modulators such as imiquimod, GM-CSF, and BCG as adjuvant therapies \[[@pntd.0008050.ref020], [@pntd.0008050.ref021], [@pntd.0008050.ref023], [@pntd.0008050.ref052], [@pntd.0008050.ref053]\]. However most of these studies were aimed at improving the efficacy of full courses of antimonials (20--30 mg/kg for 3--4 weeks), but not at reducing antimonial exposure in order to improve patient safety \[[@pntd.0008050.ref054]\]. This is partly because abbreviated and low-dose treatments with antimonials had been shown to have reduced therapeutic efficacy \[[@pntd.0008050.ref015], [@pntd.0008050.ref026]\]. In our study, we used D35, a TLR9 agonist that selectively activates pDC as an adjuvant treatment to Sb^V^ in macaques challenged with *L*. *major* and showed that it improved the efficacy of a short course of low dose Sb^V^ resulting in smaller lesions that re-epithelialize faster. Assessment of the local and systemic responses to the ODN showed increased expression of type I interferon-related genes as well as the upregulation of genes linked to NK cell and macrophage activation. Importantly, the innate immune activation induced was not associated with changes in temperature, behavior, CBC, liver or renal chemistries, even at doses 10-fold over the one that was therapeutically effective in macaques \[[@pntd.0008050.ref015]\].

In the clinic, most cases of CL involve one or more painless ulcers ranging from a few mm to several cm that heal spontaneously in 3 to 18 months, although the rate varies significantly depending on the parasite strain \[[@pntd.0008050.ref001]\]. Thus, the decision to treat is driven by the number and location of lesions, and is aimed at accelerating cure, reducing scarring and diminishing the risk of dissemination or progression to mucocutaneous leishmaniasis. Antimonials have been used to treat CL since the early 20^th^ century \[[@pntd.0008050.ref055]\] and continue to be the first line of treatment in most countries due to their low cost. In endemic countries, products such as amphotericin B are only used in patients that fail 1 or 2 courses of antimonials or for special patient populations (pregnant women, patient with renal/hepatic problems, HIV co-infected) as they are expensive, require lengthy intra-hospital administration, are associated with serious adverse events, and can foster the emergence of resistant strains \[[@pntd.0008050.ref055]\]. Thus, to ensure accessibility, there is a need to identify treatments that are shorter, have reduced toxicity, improved compliance, reduced likelihood of emergence of resistance and reduced cost.

One possible approach is combining therapies with complementary mechanism of actions, particularly for patients with multiple CL lesions as well as patients with a disseminated form of CL or PKDL \[[@pntd.0008050.ref023], [@pntd.0008050.ref055]\] There are multiple studies showing that short synthetic oligonucleotides encoding one or more CpG motifs signal through TLR9 to activate the innate immune response and foster a stronger Th1 adaptive response. These have led to multiple clinical studies in infectious diseases and cancer \[[@pntd.0008050.ref056], [@pntd.0008050.ref057]\]. Most of those studies have used PS-ODNs (type B, K, or C), which can have strong pro-inflammatory effects and foster antibody production but were previously shown to be ineffective in CL \[[@pntd.0008050.ref030], [@pntd.0008050.ref058]\]. Clinical development of CpG ODN type D, which are effective in CL, has lagged behind PS-ODN due to the reduced stability during manufacture and storage. These ODN are characterized by having a core sequence with a single purine-pyrimidine-CpG-purine-pyrimidine motif flanked on both sides by 3--5 self-complementary bases on a phosphorodiester backbone capped by two phosphorothioate bases to reduce degradation. The phosphodiester backbone allows for the formation of a stem--loop conformation and/or formation of dimers \[[@pntd.0008050.ref031]\]. In addition, D-type ODN have a 3′ end poly(G) motif, which is known to self-associate via Hoogsteen base-pairing to form parallel quadruplex structures called G-tetrads when formulated in PBS or saline \[[@pntd.0008050.ref059]\]. While this complex conformation enables type D CpG ODN to localize to early transferrin receptor positive endosomes to signal through TLR-9 and induce IFNα, it makes the preparation unstable, posing formidable challenges for the synthesis, purification, and characterization of the oligos. Further, this can lead to significant lot to lot variation, hindering the clinical development of these ODN. To overcome these issues, we developed a formulation strategy that improves the stability of the compound and significantly reduces product impurities, with most of the product being present as monomers or dimers, which facilitates product manufacturing and characterization. As shown in [Fig 1](#pntd.0008050.g001){ref-type="fig"} and [S1 Fig](#pntd.0008050.s002){ref-type="supplementary-material"}, the new formulation is stable over time and induces a similar pattern of gene expression as the research grade product when used to stimulate PBMC or a TLR9 expressing cell line *in vitro*. The reduction in large aggregates or other product-related impurities was associated with a reduction in potency at higher concentrations as determined by our *in vitro* bioactivity assay. Despite this, the formulated product induced the expression of IFNα-inducible genes in vivo in a consistent and dose-dependent manner as demonstrated by the expression of IFNα inducible genes, both at the site of administration as well as systemically in PBMC and contralateral skin biopsies. It was possible that systemic induction of type I interferons could potentially be linked to adverse effects or autoimmunity. However, our treated macaques did not show evidence of IFN-linked toxicities. This is consistent with a recent study where CpG ODN designed to activate pDC to secrete type I IFNs were used as an adjuvant therapy to a checkpoint inhibitor in patients with advanced melanoma; in these patients the main adverse effects reported consisted of local injection site injuries, rash and tenderness, and flu like symptoms (fatigue, fever, chills, myalgia) that resolved quickly following cessation of the treatment \[[@pntd.0008050.ref060]\]. Further, unlike the ODN used in that study, D35 has only 2 phosphorothioate bases on each end, reducing the risk of non-specific inflammation, thrombocytopenia, and neutropenia that have been sporadically reported for PS ODN. Accordingly, in our current study we did not observe any negative responses from our dose escalation in cynomolgus macaques, such as liver enzymes, increased temperature, or change in any blood cell populations. Although we cannot rule out a short-term increase in temperature following administration of D35 as we only measured temperatures at 24 hours post administration, our results suggest that D35 would be well tolerated.

The mechanisms by which D35 improves the outcome of CL remain unclear. Our data shows that D35 induces a type I interferon response resulting in increased expression of multiple ISGs including MX1, IFIT1, IRF7, and CXCL10. Of note, CXCL10 was previously shown to mediate the therapeutic effect of TLR9 agonists in mice, and animals depleted of CXCL10 had a reduced CD8-T cell response to the parasites \[[@pntd.0008050.ref061]\]. In addition, the macaques treated with D35 had increased expression of antigen presentation markers CD80, CD86, MHC-II, and transcription factor CIITA ([Fig 6D](#pntd.0008050.g006){ref-type="fig"}). This is consistent with previous studies showing that Type D ODNs induce the rapid maturation of monocytes into DC in a type I IFN dependent manner \[[@pntd.0008050.ref033]\] as well as with reports showing that TLR9 may mediate the IL12 in response to *L*. *major* in mice \[[@pntd.0008050.ref062]\]. D35 treatment also resulted in an increase in the proinflammatory chemokines and cytokines CCL2, 3, 5, IL1β, and IL6, as well as MMP9 in the lesion, which would promote the influx and activation of monocytes ([Fig 6C and 6F](#pntd.0008050.g006){ref-type="fig"}). The association of reduced lesion size and increase in pro-inflammatory gene expression is interesting, particularly given that a recent study suggests that in mice, NLRP3 inflammasome activation and IL1β production could contribute to CD8 T cell mediated pathology in murine cutaneous leishmaniasis \[[@pntd.0008050.ref063]\]. It is, however, possible that this association exists only at one end of the CL lesion spectrum, and in the context of the self-healing lesions induced by *L*. *major* in NHPs, a monocyte recruitment and activation and a discrete increase in pro-inflammatory cytokines may contribute to limiting the severity of the lesion. Lastly, our data on gene expression in PB and skin of *L*. *major* infected-D35 treated macaques suggests that D35 induced higher levels of multiple genes associated with NK cell activation at the lesion site than were activated by the infection alone. Of note, the pattern of gene expression is not complete, as there are increased levels of granzymes B and K, SLAMF6, KLR1, as well as T-bet and Eomes, but not perforin 1 or granulysin. Human NK cell response to Leishmania is still poorly characterized, but a recent study from Caneda-Guzman describes different degrees of NK cell activation in the lesion of patients with localized and diffuse CL (*L*. *Mexicana*) and proposes that NK cells play a key role in defining the severity of the lesions \[[@pntd.0008050.ref064]\]. Lastly, D35 could increase parasite clearance by activating macrophages or neutrophils. Surprisingly, in our study, the significant reduction in lesion size in animals treated with D35 alone or D35 plus Sb^V^ was not associated with changes in parasite numbers at any point during the study. These results are different from previous studies \[[@pntd.0008050.ref030], [@pntd.0008050.ref065]\]. It is possible that this was the result of using minicircle DNA as a readout for parasite load. While this method is very sensitive and kDNA is highly abundant (10,000--20,000 copies) and stable, the method is not optimal for discriminating between live and dead parasites, and remnants of DNA may have masked differences between groups. Indeed, it was only after the study was completed at 71 DPI, that we observed a significant decrease in parasite numbers by qPCR. Additional studies will need to be done to confirm the effect of D35 on parasite load; however, multiple studies have shown that the number of parasites in a lesion does not always correspond to its severity \[[@pntd.0008050.ref055], [@pntd.0008050.ref065], [@pntd.0008050.ref066]\]. At this time, it is not possible to determine the exact mechanism by which D35 improves the outcome in the CL model, but the data show that it induces significant immune responses *in vivo* and modifies the response to the parasite.

The mechanism of action for Sb^V^ is also not clear despite it being used for almost 100 years \[[@pntd.0008050.ref055], [@pntd.0008050.ref067]\]. This is partly because Sb^V^ consists of a mixture of oligomeric structures. Sb^V^ could behave as a prodrug being reduced *in vivo* to a more active/toxic trivalent form of antimony (Sb(III)) that exhibits antileishmanial activity through inhibition of trypanothione reductase \[[@pntd.0008050.ref055], [@pntd.0008050.ref067]\]. Of note, it is not clear whether this reduction occurs in the parasite, the macrophages or both. In addition, Sb^V^ could act as an inhibitor of type I DNA topoisomerase leading to reduced ATP (adenosine triphosphate) and GTP (guanosine triphosphate) synthesis. Lastly, more recent studies suggest that Sb^V^ could enhance parasite killing by macrophages through an increase in TNFα, ROS, and NO levels. Interestingly, studies in mice suggest that Th1 responses enhance the leishmanicidal effect of Sb^V^\[[@pntd.0008050.ref055]\]. It is known that HIV-infected patients, who have low levels of T cells, respond poorly to Sb^V^. Therefore, it is possible that D35 enhances the effect of a low-dose abbreviated course of Sb^V^ by increasing the levels of NO, ROS and Th1, enhancing the leishmanicidal effect of Sb^V^ while modulating the inflammation of the site and reducing the severity of the lesions. Regardless of the underlying mechanism of action, our study suggests that the use of D35 as an adjuvant therapy can improve the efficacy of low dose Sb^V^ treatment thereby reducing the patient's exposure and diminishing the risk of adverse effects. This approach could result in improved patient compliance and accelerated healing, helping curve the emergence of resistance. The results presented here argue for the effectiveness of D35 in combination with Sb^V^, and future clinical trials in humans are warranted to further explore D35 as an adjunct therapy to low dose Sb^V^ treatment. Interestingly, CpG ODN type D were shown to reduce the severity of CL lesions in SIV infected macaques. Patients with HIV taking ART have the highest Sb^V^-associated toxicities \[[@pntd.0008050.ref055], [@pntd.0008050.ref067], [@pntd.0008050.ref068]\]; future studies will need to determine whether the addition of D35 as an adjuvant therapy can improve the clinical outcome in these patients. In summary, our data suggests exploring the clinical use of field-friendly, affordable, and apparently safe synthetic oligonucleotide D35 in combination with the current antimonial treatments to reduce the dose, duration and side effects of current therapies, and increase compliance is warranted.

Supporting information {#sec022}
======================

###### 

(DOCX)

###### 

Click here for additional data file.

###### Design of dose escalation study in Cynomolgus Macaques.

(TIF)

###### 

Click here for additional data file.

###### Graphical representation *L*. *major* infection and treatment study.

(TIF)

###### 

Click here for additional data file.

###### Physical characterization of ultrapure and research grade D35.

(TIF)

###### 

Click here for additional data file.

###### Low dose Sb^V^ results in recrudescence.

(TIF)

###### 

Click here for additional data file.

###### Evolution of *L*. *major* lesions.

(TIF)

###### 

Click here for additional data file.

###### Detection of gene signature in PMBCs of macaques treated with D35.

(TIF)

###### 

Click here for additional data file.

###### Gene signature in skin of macaques treated with D35.

(TIF)

###### 

Click here for additional data file.

###### Leishmania quantification by minicircle qPCR.

(TIF)

###### 

Click here for additional data file.

###### Genes in Custom NanoString code set.

(DOCX)

###### 

Click here for additional data file.

###### Ingenuity Canonical Pathways.

(DOCX)

###### 

Click here for additional data file.

###### Clinical chemistry values and temperatures for cynomolgus macaques.

(DOCX)

###### 

Click here for additional data file.

###### Genes 2-fold increased over baseline saline.

(DOCX)

###### 

Click here for additional data file.

###### Genes 2-fold increase over baseline D35.

(DOCX)

###### 

Click here for additional data file.

The authors thank Dr. Amy Rosenberg, Ashutosh Rao and Hira Nakhasi for reviewing the manuscript. Dr T. Maeda kindly provided the CAL-1 cells, Dr David Sacks prepared and provided the MHOM/IL/80/Friedlin *L*. *major* clone VI promastigotes, and Dr Hideaki Sato from GeneDesign provided the ultrapure D35. In addition, we thank Dr. John Dennis, Jill Ascher, Lewis Shankle, and the Animal Care Facility staff for their care of the non-human primates included in this study. Ian L. McWilliams and Swaksha Rachuri are fellows at the Postgraduate Research Participation Program at the Center for Drug Evaluation and Research administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Food and Drug Administration. We thank Yolanda Hawkins and the FDA Office of Translational Science and technology transfer supporting the collaboration. We thank the Dr Analia Porras, PAHO, and the WHO Demonstration Project Initiative for their support. The assertions herein are the private ones of the authors and are not to be construed as official or as reflecting the views of the Food and Drug Administration at large.

10.1371/journal.pntd.0008050.r001

Decision Letter 0

Singer

Steven M.

Deputy Editor

Satoskar

Abhay R

Associate Editor

© 2020 Singer, Satoskar

2020

Singer, Satoskar

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

11 Nov 2019

Dear Dr Verthelyi:

Thank you very much for submitting your manuscript \"CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis\" (\#PNTD-D-19-01411) for review by PLOS Neglected Tropical Diseases. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the manuscript as it currently stands. These issues must be addressed before we would be willing to consider a revised version of your study. We cannot, of course, promise publication at that time.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

When you are ready to resubmit, please be prepared to upload the following:

\(1\) A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

\(2\) Two versions of the manuscript: one with either highlights or tracked changes denoting where the text has been changed (uploaded as a \"Revised Article with Changes Highlighted\" file); the other a clean version (uploaded as the article file).

\(3\) If available, a striking still image (a new image if one is available or an existing one from within your manuscript). If your manuscript is accepted for publication, this image may be featured on our website. Images should ideally be high resolution, eye-catching, single panel images; where one is available, please use \'add file\' at the time of resubmission and select \'striking image\' as the file type.

Please provide a short caption, including credits, uploaded as a separate \"Other\" file. If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License at <http://journals.plos.org/plosntds/s/content-license> (NOTE: we cannot publish copyrighted images).

\(4\) If applicable, we encourage you to add a list of accession numbers/ID numbers for genes and proteins mentioned in the text (these should be listed as a paragraph at the end of the manuscript). You can supply accession numbers for any database, so long as the database is publicly accessible and stable. Examples include LocusLink and SwissProt.

\(5\) To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosntds/s/submission-guidelines#loc-methods>

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/> PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

We hope to receive your revised manuscript by Jan 10 2020 11:59PM. If you anticipate any delay in its return, we ask that you let us know the expected resubmission date by replying to this email.

To submit a revision, go to <https://www.editorialmanager.com/pntd/> and log in as an Author. You will see a menu item call Submission Needing Revision. You will find your submission record there.

Sincerely,

Abhay R Satoskar

Associate Editor

PLOS Neglected Tropical Diseases

Steven Singer

Deputy Editor

PLOS Neglected Tropical Diseases

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviewer\'s Responses to Questions

**Key Review Criteria Required for Acceptance?**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: The paper presented by Thacker et al is about the efficacy of one dose CpG ODN D35 with low dose antimonial treatment in L. major infected primates. Their results showed that by using this approach, macaques had smaller lesions and reduced time to re-epithelization but almost no effect on parasite load.

The manuscript is very important in the field of CL treatment especially the data presented in macaques. The main problem in this manuscript is incorporation of too many data which indeed very hard to follow. Especially the graphs are not prepared properly and are very hard to read due to used small letters on graph heading.

M\@M section

Line 151, \"Buffy coats from healthy blood donors\" Please mention healthy human blood donor?

Line 163-169: why for CAL‐ 1 cells, the combination of D35+ SbV did not use? Is there specific reason for time variation sometimes it is 24 hr for PBMC and 18hr for CAL‐ 1 cells ?

Lines 197-200: please clarify this sentence: \"CpG ODN injections were performed on alternating sides of the thorax and at least 2 inches away from a previous inoculation site\"

Line231: \"promastigotes on the forehead at three separate sites (1 on the right and 2 on the left)\"what is the reason? Why the total parasites did not injected at one point?

Line 229: Please define the treatment groups as groups 1 , 2, 3, 4 similar to the text 458-459.

Line 238: please define DPI

Reviewer \#2: Methods are comprehensive and adequate

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: Lines 305 -332: why the authors did not use macaques instead of human PBMC? What was the limitation? Please harmonize the term D35 or D ODN or ODN....it is better to use D35 throughout the manuscript. Define MX-1 in Fig 1D and E.

Line 307: please change to L. major

Line 324: what about IFN-g in Fig 1C?

Line 324: Fig 1D needs more explanation.

Line 329-332: Please make it clear which D35 did you use for whole study in primate, ultrapure or Research grade?

Fig 2 A-D: in some part the control macaque is missing (purple line), it is really hard to understand this figure very well. In this section D35 is used every 3 weeks for 6 times? Please clarify.

Fig 2 G-L: what is the orange line? G11 shown with purple line which is only appear on first injection period! Very hard to understand.

Line 353: What is the reason to have considerable expression of interferon stimulated genes (ISGs), MX-1, OAS-1, CXCL-10, and IRF7, in contralateral side of the torso?

There is no graph to show the ISGs in Figure 2. In Fig 2-C there is no control at week 18.

In Fig 2 B in contralateral side, at week 12 and 18 there is confused up and down expression for OAS1, what are the reasons?

In Fig 2 E and F, for primate C07, there is upper level of IL-6 and IL-8 in contralateral side. Altogether this graph shows lots of variation and there is no concrete conclusion. This variation is within 3 macaques. Instead of graphs, could be easier to show them in a table (mean+/- SD) with their p value.

Line 387: this section is on human PBMC and the action of Sb and D35 at in vitro. In order not to back and forth from human to macaques, highly suggest describing everything in human first and then continued with in vitro and in vivo experiments in macaques.

Line 398, The data for ISG is missing?

Why the n is different for gene and protein evaluation? In Fig 3 mentioned untreated marked as circle blue and D35 as red cube. Please define the meaning of each clearly. In Fig 3A and B, why there is different view in the case of IL-6? There is no IL-6 production at protein level.

Line 418: In section \"In vivo effects of SbV on D35 treatment\" the authors used different gene expression for macaques (MX-1, CXCL-10 and IRF-7) and in the case of human IFN-a, CXCL10, IFN-g and IL-6, why is that so?

Line 453: please indicate as group 1 (saline controls), group 2( SbV 5 mg/kg (SbV

lo), group 3 D35 1 mg/kg (D35), and group 4 (Sb lo plus D35). The Sup Fig 3 A is confusing and there are different flashes below the line with no meaning.

Line 492: the Fig 5, J is missing, should be Fig5J, L-Q.

Fig 6 D, please harmonize the y axis and all should be fixed at 10.

My major critic is in Supplementary Fig 6. This Figure is very important and should be among the essential figure not in supplementary. If there is an improvement in the lesion size, why there is no significant difference between Sb+D35 and saline or other groups. Even at D71 almost no parasite DNA was seen on saline and D35 but existed on Sb and Sb+D35. If the minicircle DNA is very stable why there are huge amount of differences between D22 and D71. It is highly suggest repeating the parasite detection with different set of primers such as RV1 and RV1 and check the differences on D11, D22 and D71.

Reviewer \#2: yes

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: Lines 568-570: need revision

Lines 668-680: it is better to use another set of primers for parasite burden and then conclude this section. This is hard to believe unless prove it by another approach

The rest of discussion is clear and reads well. It seems that different sections are written by different co-authors so some parts are written very well and some parts are very hard to understand. Therefore highly suggest improving and clarifying the result and M&M sections for reading.

Reviewer \#2: yes

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: Graphs head lines used small letters, so highly suggest to modify them.

Parasite detection is major problem. This test is highly important for their conclusion. Highly suggest to check with another set of primers such as RV1 and RV2 and compare their results with this approach.

Reviewer \#2: minor revision

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: The manuscript is very important in the field of CL treatment especially the data presented in macaques. The main problem in this manuscript is incorporation of too many data which indeed very hard to follow. Especially the graphs are not prepared properly and are very hard to read due to used small letters on graph heading.

My major critic is in Supplementary Fig 6. This Figure is very important and should be among the essential figure not in supplementary. If there is an improvement in the lesion size, why there is no significant difference between Sb+D35 and saline or other groups. Even at D71 almost no parasite DNA was seen on saline and D35 but existed on Sb and Sb+D35. If the minicircle DNA is very stable why there are huge amount of differences between D22 and D71. It is highly suggest repeating the parasite detection with different set of primers such as RV1 and RV1 and check the differences on D11, D22 and D71.

Reviewer \#2: This manuscript provides pre-clinical non-human primate evaluation of combination of new drug(adjvant) namely D35 CpG ODN and low-dose current anti-Lesihmaniasis drug (antimonials) against a neglected disease cutaneous leishmaniasis. It is a very important study as cutaneous leishmaniasis is re-emerging in the unsettled parts of the world.

Based on and following their earlier studies, they evaluated several novel applications of a novel therapy modality which can be summarized into two:

1\. They evaluated doses and safety of clinical grade D35 CpG ODN to be used in further studies in humans. They overcome preparation of reproducible D35 CpG ODN production and showed its safe administration sc.

2\. Further, they evaluated bi-modal interaction between D35 CpG ODN (a single dose sc) and low-dose antimonials. In the comprehensive experiments they concluded that low-dose and therefore safer antimonials and D35 CpG ODN are synergistically reducing the lesion sizes and duration.

Overall, the study is performed with delicate and enormous experimental design and written very well.

Specific comments:

1\. It should be better to make a specific cartoon-like scheme (like in Supp Figure 3A) in each in vivo study (that what was done and when treated and when samples collected), to ease readers' understanding.

2\. Authors checked parasite DNA in the lesions during the course of infection and did not find any difference between treatment groups. I think later time point of analysis also required.

3\. I am curious what would be the cost of 1 dose D35 CpG ODN and low dose antimonials in an adult human?

4\. Is there any potential of this new treatment regimen to be able to use for other Lesihmania spp?

Minor comments:

1\. Line 144: "a lot" is not a scientific terminology, please erase.

2\. Line 216: "where" should be "were".

3\. Line 307: Leishmania major should be written with upper letter "L".

4\. Line 484: "node" should be "role".

5\. Line 592: "and limited efficacy" needs to be erased.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosntds/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Sima Rafati, Ph.D Dept. of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran

Reviewer \#2: No
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12 Jan 2020

Dear Dr Verthelyi,

We are pleased to inform you that your manuscript, \"CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis\", has been editorially accepted for publication at PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please note: your manuscript will not be scheduled for publication until you have made the required changes.

IMPORTANT NOTES

\* Copyediting and Author Proofs: To ensure prompt publication, your manuscript will NOT be subject to detailed copyediting and you will NOT receive a typeset proof for review. The corresponding author will have one final opportunity to correct any errors when sent the requests mentioned above. Please review this version of your manuscript for any errors.

\* If you or your institution will be preparing press materials for this manuscript, please inform our press team in advance at <plosntds@plos.org>. If you need to know your paper\'s publication date for media purposes, you must coordinate with our press team, and your manuscript will remain under a strict press embargo until the publication date and time. PLOS NTDs may choose to issue a press release for your article. If there is anything that the journal should know, please get in touch.

\*Now that your manuscript has been provisionally accepted, please log into EM and update your profile. Go to <http://www.editorialmanager.com/pntd>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

\*Note to LaTeX users only - Our staff will ask you to upload a TEX file in addition to the PDF before the paper can be sent to typesetting, so please carefully review our Latex Guidelines \[<http://www.plosntds.org/static/latexGuidelines.action>\] in the meantime.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Abhay R Satoskar

Associate Editor

PLOS Neglected Tropical Diseases

Steven Singer

Deputy Editor

PLOS Neglected Tropical Diseases

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
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25 Feb 2020

Dear Dr Verthelyi,

We are delighted to inform you that your manuscript, \"CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis,\" has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Serap Aksoy

Editor-in-Chief

PLOS Neglected Tropical Diseases

Shaden Kamhawi

Editor-in-Chief

PLOS Neglected Tropical Diseases

[^1]: Daniela Verthelyi is named as an inventor on a patent covering D35 filed on April, 1999, US 7,960,356 B2 under the Serial number 60/128,898. WO2000/061151. The patent is owned by the US government and licensed to DNDi.
